BeiGene Q3 product sales up 30%; cash consumption doubles

BeiGene (NASDAQ:BGNE) Q3 results:

Product revenue: $50.1M (+30%). Collaboration revenue dried up due to end of Celgene collaboration on tislelizumab.

Net loss: ($307.4M) (-113%); loss/share: ($0.39) (-105%).

Cash consumption: ($265.0M) (-100%).

Shares down 1% after hours.

Previously: BeiGene EPS misses by $1.07, misses on revenue (Nov. 12)

https://seekingalpha.com/news/3518353-beigene-q3-product-sales-30-percent-cash-consumption-doubles